Aspirin, Salicylates & Cancer
04 February 2013 
All Nations Centre CF14 3NY

An expert academic meeting and workshop with a public lecture by Professor Sir John Burn
4th February 2013: World Cancer Day

In 1974 a trial of aspirin in the reduction of death from heart attacks which had been conducted in South Wales was reported in the BMJ. This trial led to a world-wide interest in aspirin and over 140 similar trials have confirmed the benefit of aspirin in the reduction of heart disease and stroke.

In 2010 a study of aspirin in the reduction of cancer was published in the Lancet and this was quickly followed by further reports of a marked reduction in cancer by aspirin. One of the reports was by Sir John and described a 60% reduction in cancer in patients with a high risk of colon and other cancers.

Aspirin is a salicylate. Salicylates are widespread in nature, secreted by plants in response to stress, and they may explain some of the health benefits of fruit and vegetables, and of herbal remedies.  They have many functions in nature and botanists are not surprised that a salicylate has been found to be benefit to humans.

Sir John is Professor of Clinical Genetics at Newcastle University. In addition to work on aspirin, he was involved in the study reported in the Lancet in 1991 which showed that folic acid can prevent spina bifida – a disabling congenital condition which used to be relatively common throughout Wales.

To view videos of the presentations recorded from the event, click here.

Size : 126.891 Kb
Type : pdf